Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evobrutinib - Merck Serono

Next Previous
X
Search
Drug Profile

Evobrutinib - Merck Serono

Alternative Names: M-2951; MSC-2364447; MSC2364447C

Latest Information Update: 22 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck Serono
  • Developer EMD Serono; Merck Serono
  • Class Amines; Anti-inflammatories; Antirheumatics; Phenyl ethers; Piperidines; Pyrimidines; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Encephalomyelitis; Multiple sclerosis; Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 22 Jul 2024 Discontinued - Phase-III for Multiple sclerosis (Treatment-experienced) in Germany, Georgia, France, Finland, Estonia, Croatia, Czech Republic, Colombia, Canada, Bulgaria, Bosnia-Herzegovina, Belgium, Australia, Austria, Argentina, Norway, Philippines, Moldova, Malaysia, Latvia, Belarus, USA, Greece, Lithuania, United Kingdom, Ukraine, Spain, Serbia, Serbia, Poland, Poland, South Korea, South Korea, Israel, Mexico, Mexico, Italy, Netherlands, Russia, Ukraine, Taiwan, India, Hungary, Turkey, Thailand, Switzerland, Sweden, Slovakia, Singapore, Romania, Portugal, Puerto Rico, South Africa, Saudi Arabia, Hong Kong (PO), before July 2024 (Merck Sereno pipeline, July 2024)
  • 22 Jul 2024 Discontinued - Preclinical for Encephalomyelitis in USA (PO), before July 2024 (Merck Sereno pipeline, July 2024)
  • 29 Apr 2024 EMD Serono and Merck terminate the phase III evolutionRMS 1 trial in Multiple sclerosis in USA, Ukraine, United Kingdom, Taiwan, Spain, Serbia, Russia, Poland, Netherlands, South Korea, Mexico, Italy, Israel, India, Hungary, Hong Kong, Germany, Georgia, France, Finland, Estonia, Croatia, Czech Republic, Colombia, Canada, Bulgaria, Bosnia-Herzegovina, Belgium, Australia, Austria, Argentina (PO), due to the results of EVOLUTION clinical trials, which showed that evobrutinib did not meet its primary endpoint (NCT04338022) (EudraCT2019-004972-20)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top